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Contrast enhanced magnetic resonance imaging (CE MRI) is the most sensitive tool for screening women who are at high familial risk
of breast cancer. Our aim in this study was to assess the cost-effectiveness of X-ray mammography (XRM), CE MRI or both strategies
combined. In total, 649 women were enrolled in the MARIBS study and screened with both CE MRI and mammography resulting in
1881 screens and 1–7 individual annual screening events. Women aged 35–49 years at high risk of breast cancer, either because
they have a strong family history of breast cancer or are tested carriers of a BRCA1, BRCA2 or TP53 mutation or are at a 50% risk of
having inherited such a mutation, were recruited from 22 centres and offered annual MRI and XRM for between 2 and 7 years.
Information on the number and type of further investigations was collected and specifically calculated unit costs were used to
calculate the incremental cost per cancer detected. The numbers of cancer detected was 13 for mammography, 27 for CE MRI and
33 for mammography and CE MRI combined. In the subgroup of BRCA1 (BRCA2) mutation carriers or of women having a first degree
relative with a mutation in BRCA1 (BRCA2) corresponding numbers were 3 (6), 12 (7) and 12 (11), respectively. For all women, the
incremental cost per cancer detected with CE MRI and mammography combined was d28284 compared to mammography. When
only BRCA1 or the BRCA2 groups were considered, this cost would be reduced to d11731 (CE MRI vs mammography) and d15302
(CE MRI and mammography vs mammography). Results were most sensitive to the unit cost estimate for a CE MRI screening test.
Contrast-enhanced MRI might be a cost-effective screening modality for women at high risk, particularly for the BRCA1 and BRCA2
subgroups. Further work is needed to assess the impact of screening on mortality and health-related quality of life.
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Women with a known family history of breast and/or ovarian
cancer or mutations in BRCA1 and BRCA2 have a higher lifetime
risk of breast cancer than the general population with tumours
often occurring at a young age and more often being of a high
grade. Several prevention strategies for these women have been
identified including bilateral prophylactic mastectomy, chemopre-
vention and screening with annual mammography (Liberman,
2004; McIntosh et al, 2004).
Current guidance in the UK recommends that all women aged
40–49 years with a moderate risk (lifetime risk 417%) should be
offered annual mammographic surveillance (McIntosh et al, 2004).
There is, however, some concern about the poor sensitivity of
mammography due to mammographically dense breast tissue in
younger, premenopausal women and tumours resulting from gene
mutations may potentially have a more aggressive phenotype
(Liberman, 2004).
Over the last decade, magnetic resonance imaging (MRI)
has emerged as a potential investigation for the detection
and diagnosis of breast cancer and, unlike mammography,
it is not affected by breast density. This has prompted a
number of investigators to evaluate the feasibility of MRI in
a screening context.
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resonance imaging screening of women at high familiar risk of
breast cancer (MARIBS) that was set up to compare the sensitivity
and specificity of contrast-enhanced magnetic resonance imaging
(CE MRI) with two-view mammography (Leach et al, 2005). This
study and other prospective screening studies (Kriege et al, 2004;
Warner et al, 2004; Kuhl et al, 2005) consistently showed that
CE-MRI is significantly more sensitive than X-ray mammography
(XRM) in a high-risk population.
There is some concern, however, that the reported lower
specificity of CE MRI compared to mammography in three of
these studies (Kriege et al, 2004; Warner et al, 2004; Leach et al,
2005) will require more short-term follow-up and additional
costly investigations. Moreover, CE MRI is more sparsely
available, requires more highly trained personnel, costly facilities
and consumables, most notably the contrast medium. There-
fore, evidence is needed to decide whether the potential
benefits justify the additional costs required for implementing
CE MRI in a surveillance programme for women at high familial
risk of breast cancer.
Using data from the MARIBS study, the objective of this paper
was to evaluate the cost-effectiveness of mammography alone
(XRM), CE MRI alone, or mammography (XRM) in combination
with CE MRI.
MATERIALS AND METHODS
Overview
The perspective of this economic analysis is that of the UK
National Health Service, and all costs are reported in 2003 sterling
prices including VAT. We used additional cancer detected as
the measure of effectiveness corresponding to the clinical study
(Leach et al, 2005).
Clinical study
Full details of the design and the results of the clinical study have
been published elsewhere (Leach et al, 2005). Briefly, the aim of
this study was to compare the diagnostic accuracy of CE MRI and
XRM. Women aged 35–49 years at high genetic risk of breast
cancer (40.9% per annum) were recruited between 1997 and 2004
from 22 centres in the UK when they fulfilled one the following
entry criteria: tested carriers of a deleterious BRCA1 or BRCA2 or
TP53 mutation, first degree relative of someone with a BRCA1
or BRCA2 or TP53 mutation or a strong family history of breast or
ovarian cancer (Brown et al, 2000b). All participants were offered
annual screening with both CE MRI and mammography.
Mammography was performed according to the standards of the
National Health Service Breast Screening Programme (NHSBSP).
This was usually using two-view, but in a minority (7%) only one-
view was taken (mediolateral oblique only). Screening CE MRI
was undertaken utilising a specified protocol (Warren et al, 2005)
and gadopentetate dimeglumine (Magnevist
s, Schering Health-
care, UK) as contrast medium (bolus intravenous injection of
0.2mmolkg
 1 body weight). Both mammography and MRI were
independently double reported (taking the most conservative
score). True cancer status was ascertained by pathology (when a
biopsy was taken) or by the absence or presence of interval cancers
in the year after the screening event. In correspondence with the
clinical analysis presented in the main study findings (Leach et al,
2005), the economic analysis is based on the 649 women who were
both screened with CE MRI and mammography resulting in 1881
screens (1–7 screens over the 7 years of annual follow-up).
Number of recalls
In the clinical study, a women was recalled for further assessment
after a query was raised by a screening event on either or both
modalities and a review of the results of both screening tests was
performed by the supervising radiologist as an integrated whole. A
radiologist and the subject’s clinically responsible physician then
made the choice of diagnostic pathway.
For the cost-effectiveness analysis it was, however, necessary to
determine the number of women who would have been recalled for
further assessment if the screening technology had been either
mammography alone or CE MRI alone or both. We assumed that a
recalled woman in the study would have been recalled on the basis
of mammography alone if the first and second mammography
reading was abnormal regardless of the CE MRI finding or if either
the first or second mammography reading was abnormal and
the CE MRI was normal. In the case of discordant mammography
readings together with one and/or two abnormal CE MRI
readings, it was not clear whether the woman would have been
recalled on the basis of mammography alone because it is usual
practice in the UK breast screening programme to resolve such
cases by consensus or arbitration. In these cases, an additional
radiologist who was blinded to the CE MRI results undertook a
third reading of the mammograms in order to simulate these
conditions. We considered women recalled on the basis of
mammography alone when two of the three readers reported an
abnormal mammography finding. We assumed that a recall on the
basis of the CE MRI alone would have taken place if the first and/or
second reading of the CE MRI were abnormal regardless of the
mammography findings because, in practice, abnormal findings
from either MRI reader were acted on. These assumptions are
summarised in Box 1.
Box 1 Summary of assumptions regarding recall
X-ray mammography CE MRI
Scenario Reader 1 Reader 2 Reader 1 Reader 2 Recall
Recalled on the basis of X-ray mammography alone?
1 Abnormal Abnormal — — Yes
2 Normal Abnormal Normal Normal Yes
3 Abnormal Normal Normal Normal Yes
4 Abnormal Normal Abnormal Normal ? (-Third reader)
5 Abnormal Normal Normal Abnormal ? (-Third reader)
6 Normal Abnormal Abnormal Normal ? (-Third reader)
7 Normal Abnormal Normal Abnormal ? (-Third reader)
Recalled on the basis of CE MRI alone?
8 — — Abnormal Normal Yes
9 — — Normal Abnormal Yes
10 — — Abnormal Abnormal Yes
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We estimated the cost associated with the screening itself and
the costs associated with further investigations that were necessary
to establish the final diagnosis for each recalled woman.
Information on the type and number of all further investigations
(including further mammograms, supplementary MRI screening
studies, ultrasound, fine needle aspiration cytology, core biopsy,
MRI-guided biopsy and surgical biopsy) was recorded within the
MARIBS study.
Unit cost
The cost associated with the screening tests and further investiga-
tions was estimated using information from five participating
centres that screened the majority of the patients enrolled in the
study, supplemented by data on unit costs from published national
sources (Department of Health, 2005). Unit costs at 2003/2004
prices were based on the resources used in the study, the actual
annual throughput of patients and the requirements of the
research protocol (Brown et al, 2000a,b). We collected information
on staffing levels and timings for each phase of the screening and
diagnostic tests, consumables, equipment and maintenance costs,
capital charges and overheads. We then estimated the annual cost
of equipment using lifetime estimates provided by the staff at the
centres and a discount rate of 3.5% (NICE, 2004). The price for the
contrast medium was based on the average weight of the women
enrolled in the study, assuming no shared use of bottles. Staff time
was costed assuming the midpoint of the annual salary scale plus
oncosts (employer’s National insurance and pension contribu-
tions) for each member of staff and published information on staff
hours (Curtis and Netten, 2004).
Nevertheless, the unit cost associated with the research based CE
MRI screening procedure is likely to represent an overestimate
of the costs incurred in routine clinical practice because of
the specific requirements of the research protocol used in the
MARIBS study (Brown et al, 2000b). Improved CE MRI protocols
for routine clinical practice will require less time for the MRI
examination and subsequent analysis than dictated by the research
protocol, which was designed to collect additional information to
determine which features of a range of potential measurements
provided the most sensitive and specific assessment of breast
cancer (Brown et al, 2000b). Other cost reducing factors in routine
practice are lower MRI equipment costs (compared with the highly
specified systems purchased by research centres), more experi-
enced radiologists working in breast CE MRI (Warren et al, 2005)
and the possible introduction of generic formulations of Gd-DTPA
coupled with potential lower dose than o0.2mmolperkg (Knopp
et al, 2003). We therefore estimated alternative unit cost based on
the following assumptions:
  Equipment costs of d700000;
  reduction of examination time by 36% (30min instead of
47min);
  reduction of time for analysis by 50% (15min instead of
30min);
  50% reduction for cost of contrast medium (due to generic
formulation of Gd-DTPA or a lower dose of 0.1mmolkg
 1 body
weight);
  5000 annual examinations per MRI machine (assuming
10h running time of a scanner and 30min duration per
examination).
All other resource use estimates were taken as means from
the five centres that participated in our costing survey. This
cost estimate is used in the base case analysis. The other CE MRI
unit cost estimate, based on the requirements of the research
protocol, is used in sensitivity analyses. A breakdown of these
unit costs associated with these different CE MRI factors is
presented in Table 2.
Statistical analyses
We used STATA (version 8.0) for general statistical analyses and
Markov Chain Monte Carlo (MCMC) as implemented in the freely
available software WinBUGS (Spiegelhalter et al, 2000) for the
uncertainty analysis. Given that costs were incurred in the
first year of the analysis, costs and outcomes were not discounted.
Cost-effectiveness analysis was undertaken to relate differential
mean costs and the number of cancers detected associated
with mammography alone, CE MRI alone and a combined strategy,
with incremental cost-effectiveness ratios (ICERs) calculated, as
appropriate.
To account for uncertainty due to sampling variation, we
used the net-benefit approach implemented in the statistical model
depicted in equation (1). We plotted cost-effectiveness
acceptability curves (Fenwick et al, 2001) showing the probability
of one screening strategy being cost-effective compared to the two
alternative screening strategies for different levels that a decision
maker is willing to pay for an additional cancer detected. The
probability that either mammography or CE MRI or mammo-
graphy and CE MRI combined detected a cancer; the probability of
recall was modelled using multinomial distributions. The cost
associated with further investigations was modelled using a
lognormal distribution. All parameters were given vague priors
in the absence of prior information or expert opinion. The impact
of different distributional assumptions (e.g. gamma-distributions)
for the cost data was tested in sensitivity analyses (Nixon and
Thompson, 2004). The results were based on a sample of 40000
runs after a burn in period of 10000 runs had been discarded (after
assessing convergence with the Brooks Gelman Rubin diagnostic
in WinBUGS).
NB½i  ¼ pdetection½i    WTP  ð precall½i    costrecall½i Þ costscreen½i  ð1Þ
where NB[i] is the net benefit; WTP the decision maker’s
willingness to pay per cancer detected; pdetection[i] the probabi-
lity of a cancer being detected; precall[i] the probability for a
recall; costrecall[i] the cost associated with further investigations;
costscreen[i] the unit cost of screening test and index [i] indicates
screening modality.
Sensitivity analyses
We also analysed the cost-effectiveness of screening for women
with a BRCA1 (BRCA2) mutation or with a relative having a
mutation in BRCA1 (BRCA2) separately. In addition, we conducted
several one-way sensitivity analyses to assess the impact of
different unit cost assumptions (particularly CE MRI) on the
incremental cost per cancer detected.
Role of the funding source
The investigators were responsible for the study design, data
collection, data analysis, data interpretation and writing the report,
independently of all funding sources.
RESULTS
Cost of screening tests
Table 1 presents a summary of all unit costs. The cost of screening
mammography based on the five centres (d33.50) is remarkably
similar to the national average costs (d31.67; IQR d26.44–d39.65)
reported as NHS references costs (Department of Health, 2005) for
general mammography. The cost of a CE MRI screening procedure
Cost-effectiveness of CE MRI vs XRM
I Griebsch et al
803
British Journal of Cancer (2006) 95(7), 801–810 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sis d249.6 (clinical practice setting), and d405.1 (research setting)
and thus approximately 7.5 and 12 higher than mammography.
Table 2 shows a breakdown of cost associated with CE MRI. Key
components are the costs for the contrast medium (26%); cost
associated with staff (29%) and overhead/capital costs (18%).
Recalls and health outcomes
In the main study, 279 women were recalled for further
investigations. Of those, 26 women were recalled with one or two
abnormal CE MRI readings and with discordant mammography
readings. As described in the Materials and methods section,
additional reporting undertaken by a third radiologist who was
blinded to both previous CE MRI and mammography reports
resulted in 15 normal and six abnormal results. In five cases, the
mammograms could not be retrieved from individual screening
centres. In these cases, we assumed that a woman would not
have been recalled on the basis of mammography alone, but tested
this assumption in a sensitivity analysis. Based on these
assumptions, 20 fewer recalls would have been made under a
mammography only scenario with one cancer being missed (see
Table 3 for a comparison with the results of the clinical study
(Leach et al, 2005)). The resulting recall rates for the screening
modalities were 2.9% for mammography, 10.7% for CE MRI and
12.7 for both modalities combined. The number of cancers
detected by mammography was 13 (0.00691 per screen), by CE
MRI 27 (0.01435 per screen) and 33 (0.01754 per screen) by
mammography and CE MRI combined (Table 5). For the BRCA1
(BRCA2) group, the number of cancers detected was three out of
13 (6 out of 12), 12 out of 13 (7 out of 12) and 12 out of 13 (11 out
of 12) by mammography, CE MRI and CE MRI and mammography
combined respectively. Forty recalls were not justified by either the
CE MRI or mammography scores, and were thus purely on the
basis of the reader’s judgement, reflecting a cautious approach in
these high-risk individuals. Recall rates were higher in the first
study year compared to subsequent years in all three groups
(mammography 4.1 vs 2.2%; CE MRI 12.3 vs 9.9%; mammography
and CE MRI combined 15.2 vs 11.4%).
Resource use and costs
Table 4 shows the number of further investigations for all recalled
women. Both, CE MRI and mammography and CE MRI combined
would have resulted in a significant number of further investiga-
Table 1 Unit costs
Unit cost Source
Screening mammography d33.5 Participating trial centres
Screening breast CE MRI (estimated for routine clinical practice setting) d249.6 Participating trial centres
Screening breast CE MRI (based on research setting) d405.1 Participating trial centres
Repeated mammography d48.6 Participating trial centres
Repeated breast CE MRI (estimated for routine clinical practice setting) d299.2 Participating trial centres
Ultrasound d48.8 Participating trial centres
FNA d130.8 Participating trial centres
Core biopsy d176 Reference costs J27op
MRI guided biopsy d955 Participating trial centres
Surgical biopsy d984 NHS Reference costs J07
Mastectomy d2058 NHS Reference costs J03 (elective)
CE, contrast enhanced; MRI, contrast enhanced magnetic resonance imaging.
Table 2 Breakdown of unit costs for CE MRI screening procedure
Unit cost item Research CE MRI (mean, range)
Estimate for unit costs of CE MRI
in a routine clinical practice setting
Staff costs
Patient preparation d9.7 (d5.3–d18.9) d9.7
Taking scan d29.1 (d15.8–d40.6) d18,6
a
Analysis d69.0 (d34.5–d92.0) d34.5
b
Reporting d11.3 (d3.0–d17.3) d11.3
Total staff costs per screen d119.1 (d87.1–d153.2) d74.1
Equipment and maintenance
Equipment d1072951 (d914755–d1250000) d700000
Maintenance d75800 (d54000–d106000) d75800
Yearly throughput 2962 (1000–3806) 5000
c
Total equipment cost per screen
d d76.9 (d43.1–154.6) d32.0
Others
Consumables d32.2 (d12.5–d44.3) d32.2
Contrast medium d131.3 (d120.0–d135.4) d65.6
e
Overheads/capital charges d45.8 (d34.9–d61.8) d45.8
Total cost d405.1 (d320.9–d506.2) d249.6
aReducing time for taking scan by 36% (30min instead of 47min) with the same staff configuration.
bReducing time for analysing scan by 50% (15min instead of 30min) with the
same staff configuration.
c10h running time and 30min examination time.
dEquipment costs were discounted at 3.5% (assuming 10 years life span).
eCost of contrast medium
reduced by 50% (generic formulation and/or lower dose (0.1mmolkg
 1 body weight)); CE-MRI, contrast enhanced magnetic resonance imaging.
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stions. The highest mean cost associated with further investigations
resulted from CE MRI (d506.4) compared to d282.8 for
mammography and d399.5 for mammography and CE MRI
combined (Table 5). When the additional seven MRI studies
were taken into account in the mammography group, the recall
costs would have been d321.6 for this group. The mean total costs
per screen were d41.7 for mammography, d304.0 for CE MRI and
d342.4 for mammography and CE MRI combined. When
considering only the BRCA1 (BRCA2) group, the total mean costs
per women screened were d43.7 (d55.7) for mammography, d323.0
(d317.5) for CE MRI and d361.2 (d369.3) for mammography and
CE MRI combined.
Cost-effectiveness
Cost-effectiveness is summarised in Table 5. These results suggest
that the additional cost per additional cancer detected is d28284
for mammography and CE MRI combined compared with
mammography, after excluding CE MRI for extended dominance
(ICER is higher compared to the next, more effective alternative
(Drummond et al, 2005)). Given that the addition of mammo-
graphy to CE MRI did not result in any additional cancer detected
in the BRCA1 group, the cost-effectiveness could only be computed
for the comparison of CE MRI to mammography alone. In this
subgroup, the additional cost per additional cancer detected by CE
MRI would be d11731. For the BRCA2 group, the cost per
additional cancer detected equates to d15302 for CE MRI and
mammography combined after excluding CE MRI for extended
dominance.
Addressing uncertainty
Uncertainty around these estimates is represented by cost-
effectiveness acceptability curves, which show the probability that
one of the three screening combinations/options is cost-effective
compared to a maximum willingness to pay that decision makers
might have for these health outcomes (Figures 1 (for all women), 2
and 3 (for the BRCA1 and BRCA2 groups only)). For all women,
the probability of CE MRI and mammography combined would be
cost-effective is 0.07 for a decision maker’s willingness to pay of
d20000 per cancer detected, or 0.67 for d30000 per cancer
detected.
Sensitivity analyses
When gamma-distributions were used to model costs instead of
lognormal distributions, the corresponding probabilities were 0.06
and 0.65 respectively. For the BRCA1 (BRCA2) group, the
probability that CE MRI and mammography combined would be
cost-effective would be 0.57 (0.82) and 0.71 (0.96) for a decision
maker’s willingness to pay per cancer detected of d20000 and
d30000 respectively. Again, the use of gamma-distributions to
model the costs associated with further investigations did not
substantially alter our conclusions. The cost-effectiveness of CE
MRI screening is most sensitive to the costs associated with the CE
MRI screening test. Figure 4 shows the dependency of the
incremental costs per cancer detected at different CE MRI costs
and different levels of costs associated with further investigations
to obtain the final diagnosis. As pointed out earlier, particularly
lower recall rates and a reduced frequency of additional CE MRI
examinations will result in lower costs to establish the final
diagnosis. The incremental costs per cancer detected increased to
d44564 for all women, d19068 for the BRCA1 group and d22890
for the BRCA2 group when we used the unit costs of CE MRI based
on the research setting (d405.1). The cost-effectiveness of CE MRI
alone or in combination with mammography improves when only
the prevalent screen is considered (Table 6).
Table 4 Number of further procedures when recalled (all women)
Recall generated by
Procedure
Mammography
(N¼54), n (%)
CE MRI
(N¼202), n (%)
Mammography
with CE MRI
(N¼239), n (%)
Further XRM 23 (43) 21 (10) 39 (19)
Further MRI 7
a (13) 135 (67) 137 (57)
Ultrasound 38 (70) 148 (73) 173 (72)
FNA 11 (20) 56 (28) 60 (25)
Core biopsy 17 (31) 30 (15) 38 (16)
MR-guided biopsy — 13 (6) 13 (5)
Surgical biopsy 8 (15) 15 (7) 19 (8)
Mastectomy — 1 (0.5) 1 (0.4)
aThese seven further MRI studies were not considered for calculation of costs
attributable to recall procedures. CE MRI, contrast enhanced magnetic resonance
imaging; XRM, X-ray mammography.
Table 3 Number of recalls in study and analysis
Study results
a
Hypothetical scenario used in the cost-effectiveness
study- recalls on the basis of CE MRI
alone or mammography alone
b
All recalled women (N¼279)
c
XRM  XRM+ Total XRM  XRM+ Total
CE MRI  40 (2) 37 (6) 77 (8) 40 (2) 37 (6) 77 (8)
CE MRI+ 165 (19) 37 (8) 202 (27) 185 (20) 17 (7) 202 (27)
Total 205 (21) 74 (14) 279 (35) 225 (22) 54 (13) 279 (35)
Only BRCA 1 group (N¼75)
d
CE MRI  11 (1) 8 (0) 19 (1) 11 (1) 8 (0) 19 (1)
CE MRI+ 44 (9) 12 (3) 56 (12) 52 (9) 4 (3) 56 (12)
Total 55 (10) 20 (3) 75 (13) 63 (10) 12 (3) 75 (13)
Only BRCA 2 group (N¼42)
e
CE MRI  7 (1) 8 (4) 15 (5) 7 (1) 8 (4) 15 (5)
CE MRI+ 23 (5) 4 (2) 27 (7) 24 (5) 3 (2) 27 (7)
Total 30 (6) 12 (6) 42 (12) 31 (6) 11 (6) 42 (12)
Cancer in parentheses; patient numbers refer to recalled cases only.
aStudy results refer to the result of the clinical study (Leach et al, 2005).
bFor underlying assumptions see
Materials and Methods section (number of recalls).
cOut of 649 women enrolled in the study.
dOut of 139 women in the BRCA1 group.
eOut of 86 women in the BRCA2 group.
CE MRI, contrast enhanced magnetic resonance imaging; XRM, X-ray mammography.
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The findings of our analysis suggest that the addition of CE MRI
to a surveillance programme for women at high familial risk
for breast cancer might be a cost-effective health care inter-
vention. This is particularly true for the BRCA1 and BRCA2
groups, which suggested that the incremental cost per detected
cancer with CE MRI (combined with mammography or with CE
MRI alone) is d11800 and d15300 respectively when compared to
mammography alone.
Our results were most sensitive to the estimate of unit cost for
one CE MRI screening examination. A number of factors support
our assumptions underlying the lower unit cost estimate associated
with the CE MRI screening tests used in the base case analysis.
Firstly, adapted CE MRI protocols might be developed that require
less time for the MRI examination and subsequent analysis than
dictated by the research protocol (Warren et al, 2005) used in our
pragmatic cohort study. Specific analysis software implemented on
the MRI system promises to make analysis even easier. Secondly,
due to the rapidly evolving developments of MRI technology,
further reductions in equipment costs are likely to result in
lower equipment costs per screening examination. Thirdly, there
are likely to be cost reductions with regard to the contrast medium:
a lower dose (0.1mmolkg
 1 body weight) of Gd-DTPA has been
shown to be similarly effective (Knopp et al, 2003) compared to
0.2mmolkg
 1 used in our study and in addition, the expected
availability of a generic formulation. Further cost reductions can
be expected due to the increasing experience of radiologists with
this new technique, resulting in a reduction of recalled cases as
shown in a recent report (Warren et al, 2005). This will be further
complemented by improvements in routine analysis software,
Table 5 Outcomes and costs per patient screened
Mammography CE MRI Mammography with CE MRI
Cost related to screening d33.5 d249.6 d283.1
Recall rate 2.9%
a 10.7% 12.7%
Cost of further investigations when recalled d282.8 (379.7) d506.4 (399.4) d399.5 (413.4)
Cost of further investigations per screen d8.1 (79.3) d54.4 (204.1) d59.3 (213.2)
Total cost per screen d41.7 (79.3) d304.0 (204.1) d342.4 (213.2)
Number of cancer detected per screen 0.00691 0.01435 0.01754
Cost per additional cancer detected — Dominated
b d28284
Total cost per screen (BRCA1 only) d43.7 (89.8) d323.0 (230.0) d361.2 (236.5)
Number of BRCA1 cancer detected 0.00794 0.03174 0.03174
Cost per additional cancer detected- BRCA 1only — d11731 —
Total cost per screen (BRCA2 only) d55.7 (149.7) d317.5 (249.3) d369.3 (290.1)
Number of BRCA2 cancer detected 0.02459 0.02869 0.04508
Cost per additional cancer detected- BRCA 2 only — Dominated
b d15302
aBased on assumptions outlined in Materials and Methods section.
bExtended dominance (incremental cost-effectiveness ratio is higher than for next, more effective alternative).
()¼s.d.; CE MRI, contrast enhanced magnetic resonance imaging.
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Figure 1 Cost-effectiveness acceptability curve (all women). Curve
shows the probability that a screening modality is cost-effective for a range
of decision makers’ maximum willingness to pay per cancer detected.
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Figure 2 Cost-effectiveness acceptability curve for women with
mutation in BRCA1 or with a first degree relative with mutation in BRCA1.
Curve shows the probability that a screening modality is cost-effective for a
range of decision makers’ maximum willingness to pay per cancer detected.
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Figure 3 Cost-effectiveness acceptability curve for women with
mutation in BRCA2 or with a first degree relative with mutation in
BRCA2. Curve shows the probability that a screening modality is cost-
effective for a range of decision makers’ maximum willingness to pay per
cancer detected.
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stogether with continuing improvements in hardware allowing
more detailed definition of the characteristics of lesions.
To our knowledge, this is one of the first full cost-effectiveness
analyses of CE MRI screening of women with high familial risk.
One preliminary analysis (Tilanus-Linthorst et al, 2000) reported a
cost of EUR 13930 per detected cancer (d9511; US $ 16716) (1
Ł¼h0.6828 EUR; h1¼1.2 US $ (06.02.2006)) based on a small
sample of 109 women who were screened over a period of 4 years.
However, their analysis was based on MRI unit cost of EUR 170
(d116; US $ 204), which is probably an underestimate of the real
cost for performing contrast-enhanced breast MRI. In a recently
published modelling study, Plevritis et al. (2006) estimated that
annual screening with mammography and MRI combined
would result in two additional life years for women with BRCA1
mutations and about 18 months for women with BRCA2,
compared with women screened by mammography alone. The
estimated additional cost per extra quality-adjusted life year was
between $45000 (d24000, h35000) and $700000 depending on the
age range screened and the type of mutation. When a commonly
cited cost-effectiveness threshold of $100000 per QALY was
employed, then only screening with mammography and MRI
combined was found to be cost-effective for women with BRCA1
mutation screened between the ages of 35 and 54.
Several UK studies comparing two view with one view
mammography policies (Bryan et al, 1995; Wald et al, 1995), or
a combination of different viewing and reading policies at incident
screens (Johnston and Brown, 1999), reported incremental costs
per cancer detected of approximately d6000–d10300 per cancer
detected (costs uprated to 2003–2004 prices) in an older
population compared to the MARIBS population (Bryan et al,
1995; Wald et al, 1995; Johnston and Brown, 1999). If these
implemented interventions are considered to be an accepted
benchmark for cost-effectiveness, then our results suggests that
only screening with CE MRI combined with mammography of the
BRCA1/BRCA2 subgroups is likely to be a cost-effective screening
policy. However, due to different pathological characteristics of
cancers in mutation carriers, different screening intervals and risk
levels, comparisons to these programmes should be interpreted
with caution.
Our study has several limitations. Firstly, because of the study
design and the fact that a recall was initiated on the basis of the
results of all diagnostic tests combined, we are unable to explore
the relationship between the screening strategy that initiated the
recall and the type and number of further investigations. We have
found, however, that the frequency of FNA and ultrasound
investigations would have been similar in each group; a further
mammography would have been more likely in women recalled
on the basis of mammography alone because the lesion was
evidently visible on mammography and this was the standard and
most economic technique. A further CE MRI was more likely
in women recalled on the basis of CE MRI either alone or in
combination with mammography (Table 4) because the study
protocol provided for a follow-up CE MRI in cases where the MRI
findings were equivocal and, in some cases, it was the only
modality on which the lesion could be observed. Although this
makes sense intuitively, it is highly speculative to claim that we
would have observed the same pattern if this had been a
randomised trial. Nonetheless, we have found that the mean costs
for further tests per recalled case were lower in the mammography
group compared to the two other screening strategies. In the
sensitivity analyses, however, the incremental costs per cancer
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Figure 4 Sensitivity analyses: additional costs per cancer detected depending on the unit costs of screening CE MRI and cost associated with further
investigations. ICER¼incremental cost-effectiveness ratio (additional cost per additional cancer detected), lines represent different costs associated with
further investigations.
Table 6 Results of sensitivity analyses
Incremental cost-
effectiveness ratios
CE MRI
Mammography
with CE MRI
Only prevalent screen
All Dominated
a d22388
BRCA1 only d6489 —
BRCA2 only — d14366
All assessment costs
Increased by 50% Dominated
a d30687
Decreased by 50% Dominated
a d25880
Mammography assessment costs
Assumed to be the same as for CE MRI
(d71.67)
Dominated
a d23933
Alternative unit cost estimate CE MRI (based on research setting)
All Dominated
a d44564
BRCA1 only d19068 —
BRCA2 only Dominated
a d22890
aExtended dominance (incremental cost-effectiveness ratio is higher than for next,
more effective alternative). CE MRI, contrast enhanced magnetic resonance imaging.
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sdetected were relatively insensitive to the assumed total costs
associated with further tests.
Secondly, we did not include treatment-related costs in our
analysis but followed current methodological guidance, which
advises analysts to use the same time horizon for both costs
and outcomes (Ramsey et al, 2005). Nevertheless, since screening
will detect more cancers at an earlier stage, which is typically
associated with lower treatment costs compared to cancers with a
poorer prognostic index (Johnston, 2001), further cost savings
are likely to be realised with CE MRI as it is a more sensitive
screening modality.
Thirdly, it is not known what monetary value decision makers
attach to the intermediate outcome measure ‘cancer detected’ used
in our analysis. Therefore, comparisons of the study results are
only meaningful with cost-effectiveness studies that also calculated
a cost per cancer detected. Since the impact of early detection on
mortality and/or health-related quality of life in this population is
currently not known, we were not able to estimate life years or
QALYs gained (Plevritis, 2000; Dolan, 2001; Taylor et al, 2005). We
are presently analysing the study data to look at predicted
mortality. Findings from this research should be awaited before
calculations of a cost per life year gained/QALYs are made.
Taking the commonly cited cost-effectiveness threshold of the
National Institute for Clinical Excellence (NICE) of d20000 per
QALY (NICE, 2004; Rawlins and Culyer, 2004) with a grey area
between d20 and 40000, there would only have to be an average
gain of 0.65 (0.75) QALY per cancer detected in the BRCA1
(BRCA2) group and 1.4 QALYs for the whole group to demonstrate
acceptable cost-effectiveness for CE MRI. It should be borne in
mind, however, that this again represents an upper estimate since
potentially lower treatment costs associated with screen-detected
cancer are not considered in these calculations.
In addition to financial costs, there are significant psychosocial
costs associated with MRI breast screening in women at high risk
of breast cancer (Anderson and Walker, 2002). In a subgroup of
611 women taking part in MARIBS, we studied acceptability,
anxiety, intrusive thoughts and intention to return (Anderson et al,
2004). Overall, we found that annual mammography and CE MRI
are acceptable forms of screening for the majority of women with a
family history of breast cancer; 89% reported that they definitely
intended to return and only 1% definitely intended not to return.
However, 4% found breast MRI ‘extremely distressing’, and 47%
reported still having intrusive thoughts about the examination 6
weeks afterwards. Clearly, the psychological aspects of annual
MRM needs to be taken into account in the overall evaluation of an
annual screening programme.
There is currently no national policy in the UK regarding
screening women at high risk using CE MRI. A recent survey
(personal communication) of centres that took part in the MARIBS
study has shown that, at present, almost no MRI screening is
taking place. This is largely due to a lack of funding and national
guidelines. The issue is currently under consideration by the NICE
and their findings are expected in October 2006. The MARIBS
group are now establishing a working group to make recommen-
dations regarding the screening protocol which would be
appropriate to use in a clinical service setting.
In conclusion, we have shown that CE MRI in combination with
mammography is a potential cost-effective screening technique for
women at high familial risk for breast cancer. Further research is
needed to determine whether an early detection results in a
measurable increase in quality-adjusted life expectancy.
Anticipated technical improvements in MRI technology together
with an optimised use in a routine screening setting suggest
potentially lower cost for a CE MRI test than calculated in our
study setting. Therefore, we would recommend revising the cost-
effectiveness estimates presented here as soon as new evidence
emerges (Sculpher et al, 1997).
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below:
Study Staff (past and present)
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RJC Hoff (Assistant Study Coordinator)
K Chan (Data Manager)
M Khazen (Image Analysis Physicist)
RML Warren (Study Radiologist)
J Anderson (Health Psychologist)
C Levesley (Psychology Research Assistant)
I Griebsch (Health Economist)
D Thompson (Statistician)
C Hayes (Study Physicist)
R Gregory (Study Physicist)
M Sydenham (Acting Study Coordinator)
K Bletcher (Data Manager)
GP Liney (Study Physicist)
B Browne (Data Manager)
Data Monitoring and Ethics Committee
K McPherson (Chairman, Visiting Professor of Public Health
Epidemiology)
R Blamey (Professor Emeritus and Consultant Breast Surgeon)
SW Duffy (Professor of Cancer Screening).
Trial Steering Committee
A Howell (Chairman, Professor of Medical Oncology)
D Easton (Study Statistician, Genetic Epidemiologist)
DG Evans (Study Representative, Consultant Geneticist)
JE Husband (Host Institution Representative, Professor of
Radiology)
E Maher (Independent Member, Professor of Medical Genetics)
MJ Michell (Independent Member, Consultant Radiologist)
RML Warren (Study Radiologist, Consultant Radiologist)
W Watson (Consumer Representative, Founder of the Heredi-
tary Breast Cancer Group).
Recruiting centres (Number of women recruited)
Aberdeen: NE Haites, B Gibbons, H Gregory, M McJannett,
L McLennan (29); Belfast: PJ Morrison, L Jeffers (12);
Birmingham: T Cole, L Burgess, CmcKeown, JEV Morton (24);
Bristol Royal Infirmary: Z Rayter (3);
Cambridge: J Mackay, J Rankin, LG Bobrow, S Downing,
S Everest, A Middleton, B Newcombe (67);
Dundee: D Goudie, D Young (24);
Edinburgh: M Steel, EDC Anderson, J Campbell, JM Dixon,
P Walsh (60);
Frenchay Hospital
Bristol: SJ Cawthorn, M Shere, C Dawe (29);
Glasgow: R Davidson, CM Watt (20);
Guy’s and St Thomas’ London: SV Hodgson, S Watts (43);
Leeds: C Chu, G Turner, E Hazell, L Rae (55);
Liverpool: I Ellis, J Birch, C Holcombe, S Holcombe, K Makinson
(16);
Manchester Regional Genetics Service: DG Evans, G Hall,
A Shenton (157);
Newcastle: F Douglas, G Seymour (111);
Northwick Park: J Paterson, C Cummings, L Jackson (9);
Sheffield: OWJ Quarrell, JA Cook, D Kumar (14);
Southampton: DM Eccles, G Crawford, S Goodman (34);
Sutton and St George’s (or collaborators who referred to this
centre): RA Eeles, S Allan, A Ardern-Jones, E Bancroft, C Brewer,
R Carpenter, C Chapman, DL Christensen, RC Coombes, S Ebbs,
I Fentiman, S Furnell, R Given-Wilson, S Goff, S Gray, M
Greenall, G Gui, T Homfray, R Houlston, MW Kissin, I Laidlaw,
F Lennard, I Locke, AM Lucassen, F McDuff, K McReynolds, G
Mitchell,
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N Sacks, A Salmon, S Shanley, S Shrotria, N Sodha, A Stacey-
Clear, C Webster (130).
Magnetic resonance image readers (number of cases read)
Aberdeen: FJ Gilbert (132), G Needham (75);
Barnet: GR Kaplan (19);
Belfast: JG Crothers (13);
Birmingham: CP Walker (48);
Bristol Royal Infirmary: A Jones (10);
Cambridge: PD Britton (161), AK Dixon (104), R Sinnatamby
(25), RML Warren (759);
Dundee: JM Rehman (14), D Sheppard (20);
Edinburgh: J Walsh (426);
Frenchay Hospital Bristol: ID Lyburn (23), NF Slack (50);
Glasgow: LM Wilkinson (24);
Guy’s and St Thomas’ London: S Rankin (222);
Hillingdon Hospital Middlesex: K Raza (100);
Hull: G Hall (81), P Balan (47), LW Turnbull (221);
Liverpool: GH Whitehouse (47);
Manchester-Christie Hospital/Nightingale Centre: CRM Boggis
(80), E Hurley (16), A Jain (4), S Reaney (49), M Wilson (63);
Manchester Medical School: JM Hawnaur (183), J Jenkins (4);
Newcastle: A Coulthard (234), AJ Potterton (321);
Northwick Park: B Shah (57), W Teh (92);
Paul Strickland Scanner Centre London: AR Padhani (269);
Royal Hospital Haslar Gosport: PJ Buxton (2), JM Domjan (2),
PAL Gordon (6); Southampton: M Briley (55), C Rubin (72);
Sutton and St George’s: P Kessar (now at Bromley Hospitals NHS
Trust; 256); University College Hospital: MA Hall-Craggs (23).
Mammography Readers (number of films read)
Aberdeen: HE Deans (42), K Duncan (47), L Gomersall (30),
G Iyengar (3), G Needham (8);
Barnet: GR Kaplan (4); Belfast: JG Crothers (12), J McAllister
(12), JM Kirby (1);
Birmingham: S Bradley (47), MG Wallis (45);
Bristol Royal In.rmary: JE Basten (56), E Kutt (52);
Cambridge: PD Britton (185), R Davies (5), CDR Flower (9),
AH Freeman (240), D O’Driscoll (4), R Sinnatamby (310), RML
Warren (426);
Dundee: AM Cook (25), CM Walker (25);
Edinburgh: A Buttimer (55), A Gilchrist (35), BB Muir (106),
J Murray (126), L Smart (10), M Smith (8);
Glasgow: C Cordiner (18), J Litherland (16);
Guy’s and St Thomas’ London: A Jones (51), S McWilliams (76);
Hull: AE Hubbard (146);
Liverpool: A Ap-Thomas (1), DA Ritchie (33), F White (32);
Manchester-Christie Hospital/Nightingale Centre: DL Asbury
(46), U Beetles (14), CRM Boggis (212), R Dobrashian (3),
MDJ Harake (15), E Hurley (34), A Jain (20), S Reaney (74),
M Wilson (117);
Newcastle: B Kaye (55), M McElroy (180), L McLean (145),
W Wotherspoon (230);
Northwick Park: G Markham (8);
Southampton: A Bisset (2), S Hegarty (57), G Michaels (59),
N Robson (2);
Sutton and St George’s: G Brown (41), J Husband (6), KT Khaw
(1), D MacVicar (10), E Moskovic (7), J Murfitt (23).
Other radiology/magnetic resonance staff
Aberdeen: ML Muirhead, TW Redpath, S Semple;
Barnet: M Cunningham, S Turnell;
Belfast: Creynolds, R Bridcut, J Winder;
Birmingham: P Fergusson, Z Vegnuti;
Bristol Royal Infirmary: S Cowley, K Isaacs, P Richardson;
Cambridge: J Green, I Joubert, J Pinney, C Pittock, E van
Rooyen;
Dundee: SJ Gandy, P Martin, T McLeay;
Edinburgh: T Lawton, I Marshall, L Thomson;
Frenchay Hospital Bristol: H Albarran, V Blake, J Robson;
Glasgow: M Cockburn;
Guy’s and St Thomas’ London: J Goodey, K McBride;
Hull: D Fagge, S Hunter, G Liney;
Liverpool: J Chance, J Davies, Z Hussain;
Manchester–Christie Hospital/Nightingale Centre: Chammond,
W Johnson; Manchester Medical School: JE Adams, Y Watson;
Newcastle: L Lewis, M Myers;
Northwick Park: D Fox, J Johnson, J Shah;
Paul Strickland Scanner Centre, London: L Culver, R Sale,
JJ Stirling, NJ Taylor;
Royal Hospital Haslar, Gosport: E Boyd, J Evans, W Johnston,
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Southampton: A Darekar, S King, N Shepherd;
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E Scurr (on behalf of all the MRI radiographers Sutton).
Cost-effectiveness of CE MRI vs XRM
I Griebsch et al
810
British Journal of Cancer (2006) 95(7), 801–810 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s